The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The composition of the gut microbiome can control innate and adaptive immunity and has emerged as a key regulator of tumor growth, especially in the context of immune checkpoint blockade (ICB) therapy. However, the underlying mechanisms for how the microbiome affects tumor growth remain unclear. Pancreatic ductal adenocarcinoma (PDAC) tends to be refractory to therapy, including ICB. Using a nontargeted, liquid chromatography–tandem mass spectrometry–based metabolomic screen, we identified the gut microbe–derived metabolite trimethylamine N -oxide (TMAO), which enhanced antitumor immunity to PDAC. Delivery of TMAO intraperitoneally or via a dietary choline supplement to orthotopic PDAC-bearing mice reduced tumor growth, associated with an immunostimulatory tumor-associated macrophage (TAM) phenotype, and activated effector T cell response in the tumor microenvironment. Mechanistically, TMAO potentiated the type I interferon (IFN) pathway and conferred antitumor effects in a type I IFN–dependent manner. Delivering TMAO-primed macrophages intravenously produced similar antitumor effects. Combining TMAO with ICB (anti-PD1 and/or anti-Tim3) in a mouse model of PDAC significantly reduced tumor burden and improved survival beyond TMAO or ICB alone. Last, the levels of bacteria containing CutC (an enzyme that generates trimethylamine, the TMAO precursor) correlated with long-term survival in patients with PDAC and improved response to anti-PD1 in patients with melanoma. Together, our study identifies the gut microbial metabolite TMAO as a driver of antitumor immunity and lays the groundwork for potential therapeutic strategies targeting TMAO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
In the citing paper
“However, this effect appears to be context-dependent, as preclinical studies in breast159 and pancreatic cancer models160 indicate that TMAO may improve responses to ICIs (Fig. 3a).”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“For instance, TMAO and its microbial precursors reprogrammed tumor-associated macrophages toward a pro-inflammatory, type I interferon (IFN)-dependent phenotype, augmenting CD8+ T-cell activity and potentiating anti-PD-1 efficacy in murine pancreatic cancer.160”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [160]
In the citing paper
“In an orthotopic PDAC mouse model, TMAO rendered tumours responsive to anti-PD-1 and anti-TIM3 antibodies170.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs
Altschul, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.17.3389 · Cited by 73,302 · cited 2×
“Reads were aligned against a collection of CutC reference protein sequences that was downloaded through NCBI Reference Sequence Database bacterial (RefSeq), using BlastX (60) with E value < 1 × 10−7.”
MethodFast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“RNA-seq data were aligned using the bowtie2 (49) algorithm against hg19 human or mm10 mouse genome version, and the RSEM v1.”
MethodCytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“12 software (50) was used to estimate read counts and RPKM (reads per kilobase, per million mapped reads) values using gene information from human Ensembl transcriptome version GRCh37.”
MethodIntegrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508 · cited 1×
“Cell clustering, marker identification, and visualization were performed using Seurat v4 (55).”
MethodThe Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cited by
Ma, Z., Zuo, T., Frey, N., & Rangrez, A. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01946-6 · Cited by 259
“602,603 Although GF mice display anxiety-like behaviors (see discusstion in the section on the germ-free syndrome), certain gut bacteria strains, such as Bacteroides ovatus , metabolize dietary tyrosine into p-coumaric acid via the enzyme tyrosine ammonia lyase (encoded by BACOVA_01194).”
BackgroundA Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 159
“When combined with anti-PD-1 therapy, TMAO delivery led to a signi fi cant reduction in tumor burden and prolonged survival compared with treatment with TMAO or ICB alone 102 .”
BackgroundModulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 197
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
“Another bacterial metabolite, trimethylamine N -oxide, can induce type I interferon signalling and enhance ICB responses 102 but is also strongly correlated with cardiovascular disease 103 .”
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
The role of gut microbiota in intestinal disease: from an oxidative stress perspective
Sun, Y., Wang, X., Li, L., Zhong, C., Zhang, Y., Yang, X., Li, M., & Yang, C. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1328324 · Cited by 178
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
“Previous studies reported that Enterococcus and Clostridium are the major producers of trimethylamine, which is the precursor of TMAO and is associated with improved survival in cancer patients [174].”
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
Ma, K., Wang, L., Li, W., Tang, T., Ma, B., Zhang, L., & Zhang, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.011 · Cited by 135
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
“TMAO is a metabolite produced by gut bacteria through the metabolism of dietary choline and has traditionally been studied in the context of cardiovascular disease 217 , but recent findings indicate its role in modulating immune responses relevant to different types of cancer 79,218 .”
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
“In addition, Trimethylamine N-oxide (TMAO), a metabolic derivative produced by gut microbiota that helps the body metabolize choline or trimethylamine foods, has been demonstrated to enhance the antitumor immunity to pancreatic ductal adenocarcinoma in mouse models; researchers have described the mechanism by which TM…”
BackgroundZhou, L., Lyu, J., Liu, F., Su, Y., Feng, L., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305361 · Cited by 134
Conditioning of the immune system by the microbiome
Graham, D. B., & Xavier, R. J. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.05.002 · Cited by 111
Zhou, Y., Zhang, Y., Jin, S., Lv, J., Li, M., & Feng, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117031 · Cited by 102
Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 105
Trimethylamine-N-Oxide (TMAO) as a Rising-Star Metabolite: Implications for Human Health
Caradonna, E., Abate, F., Schiano, E., Paparella, F., Ferrara, F., Vanoli, E., Difruscolo, R., Goffredo, V. M., Amato, B., Setacci, C., et al. (2025) · Metabolites · doi:10.3390/metabo15040220 · Cited by 102
“Its intricate interactions with cellular metabolic pathways may also significantly contribute to tumor development [35].”
Emerging mechanisms and promising approaches in pancreatic cancer metabolism
Wu, H., Fu, M., Wu, M., Cao, Z., Zhang, Q., & Liu, Z. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06930-0 · Cited by 102
“Recent research has suggested that the microbiome-derived metabolite trimethylamine N-oxide (TMAO) may be a driver of antitumour immunity [237] and that microbiota-derived 3-IAA can in fl uence chemotherapy ef fi cacy [238].”
BackgroundMelanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Tumor microbiome – an integral part of the tumor microenvironment
Čierniková, S., Ševčíková, A., Števurková, V., & Mego, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1063100 · Cited by 93
Li, X., Shang, S., Wu, M., Song, Q., & Chen, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217096 · Cited by 92
Microbial metabolites in colorectal tumorigenesis and cancer therapy
Liu, Y., Lau, H. C.-H., & Yu, J. Q. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2203968 · Cited by 89
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
“…into TMAO in the liver, enters the blood stream, and stimulates tumor-associated macrophages to increase IFN-γ + TNF-α + CD8 + and CD4 + T cells in the tumor in a type 1 IFN-dependent manner; this increases response of pancreatic ductal adenocarcinoma (PDAC) tumors to anti–PD-1 therapy (40).”
InfluentialZhu, X., Hu, M., Huang, X., Li, L., Lin, X., Shao, X., Li, J., Du, X., Zhang, X., Sun, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.013 · Cited by 95
Li, W., Zhou, Q., Lv, B., Li, N., Bian, X., Chen, L., Kong, M., Shen, Y., Zheng, W., Zhang, J., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08385 · Cited by 88
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 77
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
“…the surface expression of activation markers such as CD86, major histocompatibility complex II (MHCII), and PD-L1, and its combination with ICIs (anti-PD1 and/or anti-Tim3) in mouse models of pancreatic cancer improved the survival rate of mice and showed better tumor treatment effects 69 (Fig.”
Prasad, R., Rehman, A., Rehman, L., Darbaniyan, F., Blumenberg, V., Schubert, M., Mor, U., Zamir, E., Schmidt, S., Hayase, T., et al. (2024) · Blood · doi:10.1182/blood.2024025366 · Cited by 78
Broadening oncological boundaries: the intratumoral microbiota
Lu, Y.-Q., Qiao, H., Tan, X.-R., & Liu, N. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.007 · Cited by 66
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, Α. (2023) · Cancers · doi:10.3390/cancers15072101 · Cited by 76
“Concomitantly, studies of mice showed promising results on the effect of bacterial metabolites on response to ICIs [117,118], granting further research.”
BackgroundInteractions between diet and gut microbiota in cancer
Nakatsu, G., Andreeva, N., MacDonald, M. H., & Garrett, W. S. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01736-4 · Cited by 67
Dysbiotic Gut Microbiota-Derived Metabolites and Their Role in Non-Communicable Diseases
Tan, J., Taitz, J., Nanan, R. K. H., Grau, G. E., & Macia, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015256 · Cited by 63
“…has been shown to improve anti-PD1 and/or anti-Tim3 immune checkpoint blockade in pancreatic ductal adenocarcinoma by potentiating IFN-g response [21] and activating CD8 T cell antitumor response, as well as by directly inducing the pyroptosis of tumour cells by increasing endoplasmic reticulum…”
BackgroundMicrobe-material hybrids for therapeutic applications
Chen, M., Xia, L., Wu, C., Wang, Z., Ding, L. S., Xie, Y., Feng, W., & Chen, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00655g · Cited by 62
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
Microbiota-derived metabolites: Key modulators of cancer immunotherapies
Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 66
“52 TMAO exhibits direct pro-inflammatory properties through the NLRP3 inflammasome and the potentiation of ISGs.”
InfluentialClinical immunotherapy in pancreatic cancer
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03632-6 · Cited by 62
The danger theory of immunity revisited
Kroemer, G., Montégut, L., Kepp, O., & Zitvogel, L. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01102-9 · Cited by 58
“Trimethylamine N -oxide produced by Clostridiales amplifies IFN-I responses in tumour-associated macrophages and mediates antitumour effects against triple-negative breast cancer, as well as sensitizing pancreatic adenocarcinomas to immunotherapy 170,171 .”
Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy
Luo, W., Li, R., Pan, C., & Luo, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1710880 · Cited by 58
Metabolites as agents and targets for cancer immunotherapy
Trefny, M. P., Kroemer, G., Zitvogel, L., & Kobold, S. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01227-z · Cited by 66
“Furthermore, vitamin B 3 sensitizes PDAC to gemcitabine-based chemotherapy in a CD4 + T cell-dependent manner 243,244 .”
InfluentialAn orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer
Zhao, K., Yu, Y., Jin, X., Pan, T. S., Zhang, S., Yang, C.-H., Rao, Z., & Zhang, X. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01904-5 · Cited by 57
The role of gut microbial metabolites in the T cell lifecycle
Tran, M. T., Huh, J. R., & Devlin, A. S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02227-2 · Cited by 61
“However, in a mouse model of pancreatic ductal adenocarcinoma, the increase in T H 1 and T H 17 cell differentiation from TMAO treatment was instead protective, promoting immune activation and antitumor immunity 49 .”
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 54
“The gut microbiome’s impact on the TME includes decreasing tumor quantity, decreasing inflammation, and slowing metastatic growth [30]; studies have implicated specific gut microbial metabolites such as TMAO in driving anti-tumor immunity [31].”
BackgroundGut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
“…axes, translation can bifurcate: butyrate may potentiate PD-1 therapy yet limit CTLA-4 efficacy; [89–92] TMAO shows tumor-promoting programs in some contexts but improves ICB response in others [34, 174–178], and can be depleted by broad-spectrum anti-biotics that also impair CAR-T potency [179].”
InfluentialGut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment
Zhou, D., & Li, Y. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2276314 · Cited by 53
“Additionally, M2 markers such as ARG1 and IL-10 are upregulated.”
BackgroundInfluentialLu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
“…(b) metabolites produced by bacteria, such as SCFAs [109, 132, 133], ino-sine [134], peptidoglycan [127], trimethylamine N -oxide (TMAO) [135, 136], neurotransmitters (including dopamine, norepinephrine, serotonin, or γ-aminobutyric acid) [137], ferrichrome [138], β-galactosidase [139],…”
Microbiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
Gut microbiota determines the fate of dietary fiber-targeted interventions in host health
Wang, W., Fan, Z., Yan, Q., Pan, T., Luo, J., Wei, Y., Li, B., Fang, Z., & Lu, W. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2416915 · Cited by 50
“88 Patients with IBS are restricted from eating foods rich in FODMAPs to avoid the fermentation of intestinal microflora to produce more intestinal gas.”
BackgroundGut microbial metabolites: Shaping future diagnosis and treatment against gastrointestinal cancer
Gou, H., Zeng, R., Lau, H. C.-H., & Yu, J. Q. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107373 · Cited by 51
The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy
Situ, Y., Zhang, P., Zhang, C., Jiang, A., Zhang, N., Zhu, L., Mou, W., Liu, Z., Wong, H. Z. H., Zhang, J., et al. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105708 · Cited by 45
“17,97,98 Additionally, TMAO derived from intratumoural microbial metabolism simultaneously activates endoplasmic reticulum stress kinases to promote cancer cell apoptosis and interacts with α -casein in breast cancer to inhibit tumour progression.”
Zheng, R., Liu, X., Zhang, Y., Liu, Y., Wang, Y.-P., Guo, S., Jin, X., Zhang, J., Guan, Y., & Liu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383978 · Cited by 48
Influence of the gut microbiota on immune cell interactions and cancer treatment
Liu, C., Fu, L., Wang, Y., & Yang, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05709-3 · Cited by 50
“In contrast, the gut microbiota metabolic product trimethylamine N-oxide, which has been shown to increase the secretion of the proinflammatory cytokines IL-6 and IL-12p4, leads to the inhibition of PDAC cells after inducing macrophage polarisation towards an M1-like phenotype [51].”
BackgroundTabrizi, E., Tabrizi, F. P. F., Khaled, G. M., Sestito, M. P., Jamie, S., & Boone, B. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434771 · Cited by 46
The Advancement and Application of the Single-Cell Transcriptome in Biological and Medical Research
Huang, K., Xu, Y., Feng, T., Lan, H., Ling, F., Xiang, H., & Liu, Q. (2024) · Biology · doi:10.3390/biology13060451 · Cited by 53
“This finding elucidates the relationship between the intestinal flora-derived metabolite TMAO and the anti-tumor immune response [123].”
BackgroundSelf-citationProteobacteria impair anti-tumor immunity in the omentum by consuming arginine
Meza‐Perez, S., Liu, M., Silva-Sánchez, A., Morrow, C. D., Eipers, P. G., Lefkowitz, E. J., Ptacek, T., Scharer, C. D., Rosenberg, A. F., Hill, D. D., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.003 · Cited by 44
Zhou, Y., Han, W., Feng, Y., Wang, Y., Sun, T., & Xu, J. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5661 · Cited by 43
“Indole‑3‑lactic acid alters chromatin accessibility to initiate the antitumor activity of CD8 + T cells and directly enhances the secretion of IFN‑ γ and granzyme B by tumor‑infiltrating CD8 + T cells to kill tumor cells, and also promotes IL‑12a secretion by binding to dendritic cells (95).”
BackgroundInfluentialRosario, S. R., Long, M. D., Chilakapati, S. R., Gomez, E. C., Battaglia, S., Singh, P. K., Wang, J., Wang, K., Attwood, K. M., Hess, S. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54565-8 · Cited by 49
“Infact,administeringTMAOdirectlyintothe abdominal cavity or via a dietary choline supplement in mice with pancreatic tumors reduced tumor growth by enhancing the T cell response in the TME 41 .”
Ischaemic heart disease in patients with cancer
Ameri, P., Bertero, E., Lombardi, M., Porto, I., Canepa, M., Nohria, A., Vergallo, R., Lyon, A. R., & López‐Fernández, T. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae047 · Cited by 40
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Gut microbial metabolites in cancer therapy
Song, P., Peng, Z., & Guo, X. (2025) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.06.016 · Cited by 38
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
Urolithin A Hijacks ERK1/2‐ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity
Ma, S., Wu, Q., Wu, W., Tian, Y., Zhang, J., Chen, C., Sheng, X., Zhao, F., Ding, L., Wang, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202310065 · Cited by 41
Optimizing Cancer Treatment Through Gut Microbiome Modulation
Kim, K., Lee, M., Shin, Y., Lee, Y., & Kim, T. J. (2025) · Cancers · doi:10.3390/cancers17071252 · Cited by 40
“In pancreatic cancer models, trimethylamine N-oxide (TMAO) improved anti-PD-1 response through enhanced immune activation [21].”
Resistance to immune checkpoint inhibitors in gastric cancer
Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 38
Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Mikhalev, A. I., Midiber, K. Y., Pechnikova, V. V., & Biryukov, A. E. (2024) · Cells · doi:10.3390/cells13171437 · Cited by 37
“…[107] -Inosine [112] -Pentanoate [97] -Short-chain fatty acids (SCFAs) [98,99,108,118] -Punicic acid [111] -Trimethylamine N-oxide (TMAO) [100] Molecular and Cell Mechanisms -Upregulation of CD80/CD86 on dendritic cells [104] -Activation of nuclear factor-κ B (NF-κ B) pathway [103]…”
BackgroundZhou, S., Liu, J., Sun, Y., Xu, P., Liu, J. L., Sun, S., Zhu, B., & Wu, H. (2023) · Food & Function · doi:10.1039/d2fo03874a · Cited by 34
Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
Chen, X., Qiu, W., Ma, X., Ren, L., Feng, M., Hu, S., Xue, C., & Chen, R. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2905182 · Cited by 37
“This indicates that the gut microbiota metabolic product TMAO can act as a driving factor for anti-tumor immunity and lays the foundation for potential therapeutic strategies targeting TMAO [104].”
BackgroundGut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors
Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 37
Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer
Hamamah, S., Lobiuc, A., & Covașă, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169026 · Cited by 36
“Additionally, pro-biotics and gut microbiota have also been shown to assist in cancer chemotherapy and immunotherapy [126,237,238,251].”
BackgroundEmerging roles of the gut microbiota in cancer immunotherapy
Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139821 · Cited by 34
“Another gut microbiotaderived metabolite trimethylamine N-oxide, identified as a driver of antitumor immunity, exhibited the ability to boost the response to ICB therapy in pancreatic cancer-bearing mouse model (67).”
BackgroundZhang, W., Qin, X., Zhang, K., Ma, J., Li, M., Jin, G., Liu, X., Wang, S., Wang, B., Wu, J., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00920-2 · Cited by 33
“Mice in the TMAO group were gavaged with TMAO at a dosage of 100 mM/0.15 mL according to previous studies [35–37], once every other day for 14 weeks, whereas the control group was gavaged with equal sterile PBS solution, once every other day for 14 weeks.”
InfluentialAnderson, S. M., & Sears, C. L. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad640 · Cited by 32
Trimethylamine N-Oxide in Aquatic Foods
Li, X., Wang, C., Yanagita, T., Xue, C., Zhang, T., & Wang, Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01974 · Cited by 32
Yin, T., Zhang, X., Xiong, Y., Li, B., Guo, D. M., Sha, Z., Lin, X., & Wu, H. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127871 · Cited by 31
Disentangling the molecular mystery of tumour–microbiota interactions: Microbial metabolites
Duan, Y.-W., Dai, J.-H., Lu, Y.-Q., Qiao, H., & Liu, N. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70093 · Cited by 31
Zeng, J., He, Z., Wang, G., Ma, Y., & Zhang, F. (2025) · MedComm · doi:10.1002/mco2.70265 · Cited by 34
“Microbiome-derived metabolite TMAO drove antitumor immunity [146].”
He, J., Li, H., Jia, J., Liu, Y., Zhang, N., Wang, R., Qu, W., Liu, Y., & Jia, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00157-9 · Cited by 34
“Delivery of TMAO to orthotopic PC– bearing mice intraperitoneally or via a dietary choline supplement reduced tumour growth and was associated with an immunostimulatory tumour-associated macrophage phenotype and activated effector T cell response in the tumour microenvironment (TME) [43].”
BackgroundThe Role of Microbiota in Pancreatic Cancer
Papa, V., Schepis, T., Coppola, G., Chiappetta, M. F., Vecchio, L. E. D., Rozera, T., Quero, G., Gasbarrini, A., Alfieri, S., & Papa, A. (2023) · Cancers · doi:10.3390/cancers15123143 · Cited by 28
“Hence, bacteria expressing CutC, an enzyme that produces TMAO precursors, was significantly reduced in PC patients [35].”
BackgroundGuan, S.-W., Lin, Q., Wu, X., & Yu, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04411-0 · Cited by 29
“Previous studies showed that intestinal bacteria can affect the ratio of TAM1/TAM2 cells in PAAD tumor-bearing mice [59], and that tumor microbiome can influence the infiltration of CD8 + T cells in the TME [7, 60, 61].”
BackgroundIntratumoral Microbiome: Foe or Friend in Reshaping the Tumor Microenvironment Landscape?
Kyriazi, A. A., Karaglani, M., Agelaki, S., & Baritaki, S. (2024) · Cells · doi:10.3390/cells13151279 · Cited by 33
“Moreover, in tumor tissues derived by long-term PDAC survivors, the intratumoral loads of the genera Bacillus and Paenibacillus were significantly elevated compared to those from short-term PDAC survivors [19,131].”
BackgroundResultGut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke
Li, Z., He, X., Fang, Q., & Yin, X. (2024) · Biomolecules · doi:10.3390/biom14111463 · Cited by 31
“FMC also significantly reduced circulating TMAO concentrations by inhibiting cutC in tumor and diet-induced obesity mouse models [76,172].”
Lü, L., Liao, J., Xu, C., Xiong, Y., Zhou, J., Wang, G., Lin, Z., Zha, K., Lin, C., Zeng, R., et al. (2025) · Advanced Science · doi:10.1002/advs.202502293 · Cited by 42
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
Vitorakis, N., Gargalionis, A. N., Papavassiliou, K. A., Adamopoulos, C., & Papavassiliou, A. G. (2024) · Cancers · doi:10.3390/cancers16162876 · Cited by 29
“Such promising metabolites produced by gut microbes include trimethylamine N-oxide (TMAO), which has been found to boost anti-tumor immunity against PDAC as well as 3-IAA, which renders PDAC cells more sensitive to chemotherapy [193,194].”
BackgroundPotential of natural products and gut microbiome in tumor immunotherapy
Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25
Gronich, N., Geva‐Zatorsky, N., Herren, R., Kelly, L., Cohen, Z., Zhou, H., Chen, Y. H., Shah, K., Robinson‐Catala, T. A., Frisby, G., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70066 · Cited by 26
“70 Clinical trials further underscore the microbiome’s influence on ICB immunotherapy outcomes.”
Microbial metabolites and immunotherapy: Basic rationale and clinical indications
Kovtonyuk, L. V., & McCoy, K. D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101755 · Cited by 27
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
“150 Inosine produced by the commensal bacterium B. pseudolongum significantly promoted TH1 cell differentiation by exerting adenosine A2A receptors on T cells in the presence of exogenous IFN-γ and enhanced the therapeutic response to ICIs.”
BackgroundGut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
“However, this effect appears to be context-dependent, as preclinical studies in breast 159 and pancreatic cancer models 160 indicate that TMAO may improve responses to ICIs (Fig.”
InfluentialGiurini, E. F., Ralph, O. G., Pappas, S. G., & Gupta, K. H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0311 · Cited by 26
“Microbial metabolites trimethylamine N-oxide rendered tumors sensitive to anti–PD-1 blockade through reprogramming TAMs to an immunostimulatory MHCII + CD86 + phenotype (80).”
Wekking, D., Silva, C. A. C., Viscò, R., Denaro, N., Lambertini, M., Maccioni, A., Loddo, E., Willard-Gallo, K. E., Scartozzi, M., Derosa, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104767 · Cited by 30
Zhang, F., Jiang, Q., Cai, J., Meng, F., Tang, W., Liu, Z., Lin, X., Liu, W., Zhou, Y., Shen, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp8266 · Cited by 31
Daniel, N., Farinella, R., Belluomini, F., Fajkić, A., Rizzato, C., Souček, P., Campa, D., & Hughes, D. J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.002 · Cited by 24
Chen, L., Li, B.-Y., Zu, M.-H., Reis, R., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 23
Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 29
Zhou, C., Basnet, R., Zhen, C., Ma, S., Guo, X., Wang, Z., & Yuan, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01178-8 · Cited by 27
“However, the immune system of nude mice is not robust, and recent studies have shown that TMAO promotes antitumor immunity in triple-negative breast cancer and pancreatic cancer [27, 28], so it is necessary to consider various factors in vivo.”
BackgroundJayaprakash, M., Kumar, D. V., Chakraborty, G., Chakraborty, A., & Kumar, V. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118559 · Cited by 24
Zhou, Y., Lv, J., Jin, S., Fu, C., Liu, B., Shen, Y., Li, M., Zhang, Y., & Feng, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1526051 · Cited by 30
The role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
“51,67 Tryptophan-derived microbial metabolites activate the AhR in TAMs to suppress antitumour immunity and reduce the efficacy of ICIs.”
BackgroundSaleem, M., Masenga, S. K., Ishimwe, J., Demirci, M., Ahmad, T., Jamison, S., Albritton, C. F., Mwesigwa, N., Haynes, A. P., White, J., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22031 · Cited by 21
“115 Together, these studies suggest that the gut microbiome plays a vital role in modulating proinflammatory immune responses, oxidative stress, and SSBP.”
Background
Metadata
- Authors
- Mirji, G., Worth, A., Bhat, S. A., El Sayed, M., Kannan, T., Goldman, A. R., Tang, H.-Y., Liu, Q., Auslander, N., Dang, C. V., Abdel-Mohsen, M., Kossenkov, A., Stanger, B. Z., & Shinde, R. S.
- Affiliations
- The Wistar Institute (US)
- Immunology, Microenvironment and Metastasis Program, the Wistar Institute, Philadelphia, PA, USA.
- University of Pennsylvania (US)
- Corresponding author
- Shinde, Rahul S.
- ORCID
- Venue
- Science Immunology
- Published
- 2022-09-30
- Volume
- 7
- Issue
- 75
- Pages
- eabn0704-eabn0704
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC9925043
- OpenAlex
- W4295519447
- Cited by
- 327
- References
- 62
- Citations by year
- 2026: 83 · 2025: 91 · 2024: 89 · 2023: 62 · 2022: 2
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10od023586-01)
- National Cancer Institute (R01CA057341, R21CA259240, R50CA221838, R50CA211199, R01CA252225, P30CA010815)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- trimethylamine N-oxide, gut microbiota, pancreatic ductal adenocarcinoma, immune checkpoint blockade, antitumor immunity, tumor-associated macrophages, type I interferon pathway, choline, CutC, anti-PD-1, effector T cells, tumor microenvironment, melanoma
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Methylamines, Pancreatic Neoplasms, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.